AN2 Therapeutics Employee Directory
Biotechnology ResearchCalifornia, United States11-50 Employees
AN2 Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule therapeutics built on a boron-based chemistry platform. Its development pipeline spans hematologic diseases, infectious diseases, and oncology, with three Phase 2 studies expected to be active in 2026, along with two preclinical candidates and additional advanced research programs targeting oncology, bone disorders, and infectious diseases. The company is headquartered in Menlo Park, California, and operates as a small-to-mid-sized biotechnology firm. Its work is geared toward patients and healthcare providers seeking new treatment options for serious conditions within its core areas, aiming to address unmet medical needs. In 2026, AN2 Therapeutics initiated a Phase 2 investigator-initiated trial of epetraborole for Mycobacterium abscessus Complex Lung Disease, marking a notable advancement in its infectious-disease program.